To include your compound in the COVID-19 Resource Center, submit it here.

GDC-0449: Preliminary Phase II data

Roche said preliminary data from a double-blind, placebo-controlled Phase II trial evaluating 150 mg/day oral GDC-0449 as a single agent maintenance therapy in 104 ovarian cancer patients in second

Read the full 290 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE